El-Gabalawy H - Search Results

1

Common denominators of inflammatory joint diseases.

El-Gabalawy H. El-Gabalawy H. J Rheumatol Suppl. 2005 Jan;72:3-6. J Rheumatol Suppl. 2005. PMID: 15660454 Review.

2

Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations.

de Moel EC, Trouw LA, Terao C, Govind N, Tikly M, El-Gabalawy H, Smolik I, Bang H, Huizinga TWJ, Toes REM, van der Woude D. de Moel EC, et al. Among authors: el gabalawy h. Arthritis Res Ther. 2023 Mar 8;25(1):37. doi: 10.1186/s13075-023-03009-7. Arthritis Res Ther. 2023. PMID: 36890568 Free PMC article.

3

Expression of N-acetyl-D-galactosamine associated epitope in synovium: a potential marker of glycoprotein production.

El-Gabalawy H, King R, Bernstein C, Ma G, Mou Y, Alguacil-Garcia A, Fritzler M, Wilkins J. El-Gabalawy H, et al. J Rheumatol. 1997 Jul;24(7):1355-63. J Rheumatol. 1997. PMID: 9228137

4

Anti-inflammatory therapy.

Canvin JM, el-Gabalawy HS. Canvin JM, et al. Phys Med Rehabil Clin N Am. 1999 May;10(2):301-17. Phys Med Rehabil Clin N Am. 1999. PMID: 10370933 Review.

5

The histopathology of early synovitis.

Hitchon CA, el-Gabalawy HS. Hitchon CA, et al. Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S28-36. Clin Exp Rheumatol. 2003. PMID: 14969047 Review.

6

A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis.

Hitchon CA, Alex P, Erdile LB, Frank MB, Dozmorov I, Tang Y, Wong K, Centola M, El-Gabalawy HS. Hitchon CA, et al. J Rheumatol. 2004 Dec;31(12):2336-46. J Rheumatol. 2004. PMID: 15570632

7

Familial seropositive rheumatoid arthritis in North American Native families: effects of shared epitope and cytokine genotypes.

Oen K, Robinson DB, Nickerson P, Katz SJ, Cheang M, Peschken CA, Canvin JM, Hitchon CA, Schroeder ML, El-Gabalawy HS. Oen K, et al. J Rheumatol. 2005 Jun;32(6):983-91. J Rheumatol. 2005. PMID: 15940756

8

Early undifferentiated arthritis.

Hitchon CA, Peschken CA, Shaikh S, El-Gabalawy HS. Hitchon CA, et al. Rheum Dis Clin North Am. 2005 Nov;31(4):605-26. doi: 10.1016/j.rdc.2005.07.006. Rheum Dis Clin North Am. 2005. PMID: 16287587 Review.

9

Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.

Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Keeling SO, et al. J Rheumatol. 2007 Mar;34(3):623-33. J Rheumatol. 2007. PMID: 17343310 Review.

10

Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.

Maksymowych WP, Landewe R, Boers M, Garnero P, Geusens P, El-Gabalawy H, Heinegard D, Kraus VB, Lohmander S, Matyas J, Saxne T, van der Heijde D. Maksymowych WP, et al. J Rheumatol. 2007 Mar;34(3):634-40. J Rheumatol. 2007. PMID: 17343311

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

163 results

Search Page